Follicular rash during therapy with erlotinib (Tarceva®);Follikuläre arzneimittelreaktion unter einer therapie mit erlotinib (Tarceva®)

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 10, 2006, Pages 855-857

  Gerdes, Sascha ^a   Mrowietz, Ulrich ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

EGF receptor; Tyrosinekinase inhibitor

Indexed keywords

AMITRIPTYLINE; BETAMETHASONE; CAPTOPRIL; CARBOPLATIN; ERLOTINIB; FUSICORT; FUSIDIC ACID; METRONIDAZOLE; NAVELBINE; PACLITAXEL; TETRACYCLINE;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CHEMOTHERAPY; CLINICAL FEATURE; DEPRESSION; DRUG ERUPTION; ERYTHEMA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MALE; PAPULE; PRURITUS; PUSTULE; SKIN DEFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FACIAL DERMATOSES; FOLLICULITIS; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PRURITUS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 33748942510     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.06088.x     Document Type: Article

References (10)

1. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-6.
2. Doroshow JH. Targeting EGFR in non-small-cell lung cancer. N Engl J Med 2005; 353: 200-2.
3. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-46.
4. Gutzmer R, Werfel T, Kapp A et al. Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt 2006; 57: 509-513.
5. Bunn PA, Jr., Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29: 38-44.
6. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4: 397-406.
7. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
8. Hansen LA, Alexander N, Hogan ME et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997; 150: 1959-75.
9. Murillas R, Larcher F, Conti CJ et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14: 5216-23.
10. Higgins B, Kolinsky K, Smith M et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004; 15: 503-12.